Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
634 results about "Small interfering RNA" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. It interferes with the expression of specific genes with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation.
Methods and compositions for therapeutic use of RNA interference
InactiveUS20030157030A1Effective amountImprove angiogenesisOrganic active ingredientsPowder deliveryGene expressionSmall interfering RNA
Abstract of Disclosure The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism, e.g., in a sequence-dependent, PKR-independent manner. In particular, the subject method can be used to alter the growth, survival or differentiation of cells for therapeutic and cosmetic purposes.
Owner:INSERT THERAPEUTICS INC
Method for expression of small antiviral RNA molecules within a cell
ActiveUS20030059944A1Prevents sequenceHigh expressionOrganic active ingredientsPeptide/protein ingredientsGeneticsViral life cycle
In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. The methods can be used to express double stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, that interfere with a viral life cycle by down regulating either the viral genome, a viral genome transcript, or a host cell that. In another aspect the invention provides methods for treating patients having suffering from infection, particularly infection with HIV.
Owner:CALIFORNIA INST OF TECH
Methods and compositions for detection of small interfering RNA and micro-RNA
InactiveUS20060019258A1Improve survivalDetermining for survivalSugar derivativesMicrobiological testing/measurementTreatment effectPhosphate
The invention provides a method of distinguishing small RNA from mRNA by contacting a biological isolate with a phosphate reactive reagent having a label moiety under conditions wherein the label moiety is preferentially added to the 5′ phosphate of small RNA over the 5′ cap structure of mRNA and distinguishing the small RNA from the mRNA according to the presence of the label. The invention further provides a method of identifying a plurality of different small RNAs by adding a unique extension sequences to different small RNA sequences and identifying the extended small RNA sequences. Furthermore, the invention provides diagnostic methods for determining presence of a disease or condition such as cancer. Also provided are prognostic methods for determining progression of a disease or condition or for monitoring effectiveness of a treatment for a disease or condition
Owner:ILLUMINA INC
Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
InactiveUS20070099196A1Solve low usageSugar derivativesMicrobiological testing/measurementGeneticsTarget mrna
The invention relates relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs (siRNAs).
Owner:EXIQON AS
RNA interference in respiratory epitheial cells
InactiveUS7297786B2Speed up the processAvoid insufficient lengthPowder deliveryBacteriaRespiratory epitheliumSmall interfering RNA
The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules.
Owner:UNIV OF IOWA RES FOUND
Inhibitor nucleic acids
InactiveUS20050256071A1Low melting pointQuality improvementOrganic active ingredientsNervous disorderAptamerHalf-life
The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism. In particular, the RNAi constructs may include one or more modifications to improve serum stability, cellular uptake and / or to avoid non-specific effect. In certain embodiments, the RNAi constructs contain an aptamer portion. The aptamer may bind to human serum albumin to improve serum half life. The aptamer may also bind to a cell surface protein that improves uptake of the construct.
Owner:CALIFORNIA INST OF TECH
Novel methods for quantification of microRNAs and small interfering RNAs
ActiveUS20050272075A1Highly sensitive and specific hybridizationHighly sensitive and specific and ligationSugar derivativesMicrobiological testing/measurementMicroRNAAllele
The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.
Owner:QIAGEN GMBH
Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
InactiveUS20070065840A1Strong specificityHigh sensitivitySugar derivativesMicrobiological testing/measurementTarget mrnaAllele
The invention relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs (siRNAs). The invention furthermore relates to oligonucleotide probes for detection and analysis of other non-coding RNAs, mRNAs, mRNA splice variants, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g. alterations associated with human disease, such as cancer.
Owner:EXIQON AS
Cell transfecting formulations of small interfering RNA related compositions and methods of making and use
InactiveUS20060019912A1Efficient deliveryOrganic active ingredientsSugar derivativesLipid formationDelivery vehicle
Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.
Owner:CHIRON CORP
METHODS OF IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERING RNA(siRNA)
InactiveUS20090053140A1Inhibition effectOrganic active ingredientsMicrobiological testing/measurementMemory formationTreated animal
The present invention relates to a method of identifying a gene or gene product associated with transcription dependent memory formation in an animal comprising the steps of: (a) administering to said animal sufficient small interfering RNA (siRNA) specific for the gene to inhibit gene function; (b) training said animal under conditions sufficient to induce transcription dependent memory formation in a normal untreated animal; and (c) determining the level of transcription dependent memory formation induced by the training of the treated animal. The present invention provides methods of using small interfering PNAs (siRNA) in hippocampus to identify genes and gene product whose inhibition affects contextual and temporal long-term (LTM) memory, but not short-term memory (STM).
Owner:HELICON THERAPEUTICS
Reagents, methods and systems to suppress pro-inflammatory cytokines
ActiveUS20080124370A1Inhibit inflammationInhibit expressionAntipyreticGenetic material ingredientsMedicineCytokine
The present invention relates to reagents, methods and systems to treat inflammation and pain in a subject using small interfering RNA (siRNA) molecules targeted to either TNFα, IL1, IL6 and other pro-inflammatory cytokines.
Owner:WARSAW ORTHOPEDIC INC
siRNA-Mediated gene silencing with viral vectors
The present invention is directed to viral vectors encoding small interfering RNA molecules (siRNA) targeted against a gene of interest, and methods of using these viral vectors.
Owner:UNIV OF IOWA RES FOUND
Method of de-differentiating and re-differentiating somatic cells using RNA
ActiveUS20110165133A1Efficient transfectionLess time-consumingBiocideEpidermal cells/skin cellsDiseaseSomatic cell
RNA prepared by in vitro transcription using a polymerase chain reaction (PCR)-generated template can be introduced into a cell to modulate cell activity. This method is useful in de-differentiating somatic cells to pluripotent, multipotent, or unipotent cells; re-differentiating stem cells into differentiated cells; or reprogramming of somatic cells to modulate cell activities such as metabolism. Cells can also be transfected with inhibitory RNAs, such as small interfering RNA (siRNA) or micro RNA (miRNA), or combinations thereof to induce reprogramming of somatic cells. For example, target cells are isolated from a donor, contacted with one or more RNA's causing the cells to be de-differentiated, re-differentiated, or reprogrammed in vitro, and administered to a patient in need thereof. The resulting cells are useful for treating one or more symptoms of a variety of diseases and disorders, for organ regeneration, and for restoration of the immune system.
Owner:YALE UNIV
In vivo high throughput selection of RNAi probes
InactiveUS20050042641A1Inhibit expressionSugar derivativesMicrobiological testing/measurementSmall interfering RNARNA
In mammalian systems, RNA interference (RNAi)-based suppression of target gene expression may be activated by delivery of RNAi probes such as double stranded small interfering RNA (siRNA) molecules or short hairpin RNAs (shRNAs), where the RNAi probe sequence is homologous to the target gene. A reliable and quantitative method is provided for the rapid and efficient identification of RNAi probes that are most effective in providing RNAi-mediated suppression of target gene expression. This method may be used for high-throughput screens to identify effective RNAi probes.
Owner:COLD SPRING HARBOR LAB INC
Small interference RNA (siRNA) molecules for modulating superoxide dismutase (SOD)
InactiveUS20060229268A1Good potencyIncrease contactNervous disorderGenetic material ingredientsProtein targetAmyotrophic lateral sclerosis
The invention pertains to using double stranded ribonucleic acid molecules such as small interfering RNA (siRNA) molecules to target an SOD gene to interfere with gene expression and SOD protein production. Method are disclosed for inhibiting expression of a target protein in a subject with a neurological disorder by introducing a small interference ribonucleic acid (siRNA) molecule into the subject with the neurological disorder, such as amyotrophic lateral sclerosis (ALS).
Owner:ALSGEN
Method for expression of small antiviral RNA molecules within a cell
In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector. The methods can be used to express double stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, that interfere with a viral life cycle by down regulating either the viral genome, a viral genome transcript, or a host cell that. In another aspect the invention provides methods for treating patients having suffering from infection, particularly infection with HIV. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle.
Owner:CALIFORNIA INST OF TECH +1
siRNA-mediated gene silencing with viral vectors
The present invention is directed to viral vectors encoding small interfering RNA molecules (siRNA) targeted against a gene of interest, and methods of using these viral vectors.
Owner:IOWA RES FOUND UNIV OF
Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same
Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating cancer off cell proliferative disorders. The bacterium includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
ActiveUS20130084605A1Reducing lactate productionIncreasing polypeptide productionAnimal cellsFused cellsLactate dehydrogenaseCulture cell
The present invention provides methods and compositions for reducing lactate production and increasing polypeptide production in cultured cells. In one aspect, the invention provides a method comprising culturing cells expressing a) a small interfering RNA (siRNA) specific for a lactate dehydrogenase (LDH) and b) an siRNA specific for a pyruvate dehydrogenase kinase (PDHK). In another aspect, the invention provides cultured cells or vectors comprising an siRNA specific for a LDH and an siRNA specific for a PDHK.
Owner:GENENTECH INC
siRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
ActiveUS20070287681A1Improve efficiencyOrganic active ingredientsSugar derivativesPolyelectrolyteHydrophilic polymers
The present invention is related to hybrid conjugates formed by covalently bonding siRNA (small interfering RNA) molecules to hydrophilic polymers for improving stability of the siRNA molecules effective for delivering the siRNA in vivo, and polyelectrolyte complex micelles formed by ionic interactions between the conjugates and multifunctional cationic compounds. The siRNA-hydrophilic polymer conjugates and polyelectrolyte complex micelles derived therefrom can be used for improving stability of the siRNA molecules in vivo. Consequently, the delivery of siRNA molecules for therapeutic applications into cells can be facilitated, and the siRNA is still active even though a small dose of the siRNA is used.
Owner:BIONEER +1
RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering RNA
InactiveUS20050261212A1Preserve activityImprove compound stabilityPeptide/protein ingredientsGenetic material ingredientsRegulator genePolynucleotide
The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications associated with Alzheimer's disease. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against NOGO and NOGO receptor (NOGOr) polypeptide and polynucleotide targets.
Owner:RIBOZYME PHARMA INC
Immunomodulatory compositions and uses therefor
The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on the host cells results in suppression of the immune response. The present invention provides agents such as antibodies, and antigen-binding fragments thereof, small molecules, aptamers, small interfering RNAs, and peptide-IgFc fusion polypeptides that interact with one or more of LAR, RPTP-δ, and RPTP-σ expressed by immune cells or interact with a polynucleotide encoding the RPTP. Also provided are RPTP Ig domain oligomers and Fc fusion polypeptides. Such agents are useful for treating an immunological disorder in a subject according to the methods described herein.
Owner:VIRAL LOGIC SYST TECH CORP
Compositions for DNA mediated gene silencing
InactiveUS7422896B1Silencing of gene expressionSugar derivativesPeptide/protein ingredientsNucleotideGene silencing
Owner:ALLELE BIOTECH & PHARMA
Complex for facilitating delivery of dsRNA into a cell and uses thereof
InactiveUS20050260756A1Avoid security issuesAvoids of availabilityMicroencapsulation basedGenetic material ingredientsGene productRNA - Ribonucleic acid
The present invention provides a membrane-permeable complex for facilitating the delivery of a double-stranded ribonucleic acid molecule into a cell. Specifically, the invention provides a membrane-permeable complex that comprises a double-stranded ribonucleic acid molecule, such as a small interfering RNA, a cell-penetrating peptide, and a covalent bond linking the double-stranded ribonucleic acid to the cell-penetrating peptide. Also provided are methods of using the membrane-permeable complex of the present invention to deliver the double-stranded ribonucleic acid molecule to a cell or to inhibit expression of a gene product by a cell.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Method and compositions for inhibiting tumorigenesis
InactiveUS20050112707A1Prevent tumorigenic effectEffective treatment regimenPeptide/protein ingredientsNervous system cellsSimple Organic CompoundsProstate cancer
The present invention relates to compounds, small interfering RNAs and compositions and methods of inhibiting tumorigenesis using agents that inhibit the sonic hedgehog and GLI signaling pathway, including agents that inhibit GLI expression, synthesis and / or function. The present invention also relates to particular biomarkers that can be used in the diagnosis and prognosis of cancer. Methods of treating cancer, including glioblastomas, medulloblastomas, basal cell carcinomas, prostate cancer and small cell and non-small cell lung cancer are also provided using small organic compounds, siRNAs and blocking antibodies that inhibit or block the SHH / GLI pathway.
Owner:NEW YORK UNIV MEDICAL CENT
Bacteria mediated gene silencing
Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The bacterium or BTP includes one or more siRNAs or one or more DNA molecules encoding one or more siRNAs. Vectors are also described for use with the bacteria of the invention for causing RNA interference in eukaryotic cells.
Owner:CEQUENT PHARMA
Inhibition of viral gene expression using small interfering RNA
InactiveUS20070149470A1Enhanced inhibitory effectBiocideSsRNA viruses positive-senseSmall interfering RNAViral gene
The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES) sequence of HCV are described.
Owner:SOMAGENICS INC
Microvesicles carrying small interfering rnas, preparation methods and uses thereof
Microvesicles containing interfering RNAs, preparation methods and uses thereof are provided. Pharmaceutical compositions and kits comprising the microvesicles containing interfering RNAs are also provided. Microvesicles containing interfering RNAs, pharmaceutical compositions and kits comprising such microvesicles can be used to study the effects of interfering RNAs on receptor cells. As microvesicles containing interfering RNAs can stably, high efficiently and specifically deliver interfering RNAs, microvesicles containing interfering RNAs can be used to treat related diseases.
Owner:MICROMEDMARK BIOTECH CO LTD
Novel sirna structure for minimizing off-target effects and relaxing saturation of rnai machinery and the use thereof
InactiveUS20120238017A1Enhanced gene silencing effectsSolve the real problemSugar derivativesActivity regulationNucleotideSense strand
The present invention relates to a novel siRNA structure and the use thereof. More particularly, the invention relates to a double-stranded small interfering RNA molecule (siRNA molecule) comprising a 19-21 nucleotide (nt) antisense strand and a 15-19 nt sense strand having a sequence complementary to the antisense sequence, wherein the 5′ end of the antisense strand has a blunt end and the 3′ end of the antisense strand has an overhang, and to a method for silencing the expression of a target gene using the siRNA molecule.
Owner:OLIX PHARMA
Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA
InactiveUS20060178328A1Reduce riskImprove memory functionNervous disorderSpecial deliveryDna encodingSmall interfering RNA
The present invention relates to devices, systems, and methods for improving memory and / or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The present invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and / or cognitive function in a subject.
Owner:MEDTRONIC INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com